Diroximel Fumarate (DRF) in Patients With Relapsing-Remitting Multiple Sclerosis: Interim Efficacy and Safety Results From the Phase 3 EVOLVE-MS-1 Study (P3.2-060)

Objective: null To explore clinical and radiological disease outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with diroximel fumarate (DRF) in EVOLVE-MS-1. null Background: null DRF (formerly ALKS 8700; BIIB098) is a novel fumarate being developed for relapsing forms of MS. DRF is expected to have similar efficacy as dimethyl fumarate (both are converted to monomethyl fumarate), with the potential for a...